Q4FY21 Result Update - Sun Pharmaceutical Industries - ICICI Direct

Q4 revenues grew 4.1% YoY to Rs. 8523 crore (I-direct estimate: Rs. 8760 crore). Indian formulations grew 12.9% YoY to Rs. 2671 crore. US formulations remained subdued at Rs. 2695 crore, down 0.7% YoY. Emerging markets business grew 3.5% YoY to Rs. 1402 crore. RoW Markets business grew 6.3% YoY to Rs. 1191 crore. API segment de-grew 9.9% YoY to Rs. 473 crore. EBITDA margins expanded 738 bps YoY to 24.0% (I-direct estimates of 23.0%) mainly due to lower other expenditure and better gross margins. Subsequently, EBITDA grew 50.3% YoY to Rs. 2048 crore (I-direct estimate: Rs. 2015 crore). Adjusting for exceptional items, PAT more than doubled (~2x) to Rs. 1343 crore (I-direct estimate: Rs. 1455 crore).

For details, click on the link below: Link to the report

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.668.3 as compared to the previous close of Rs. 669.65. The total number of shares traded during the day was 563930 in over 12315 trades.

The stock hit an intraday high of Rs. 675.4 and intraday low of 659. The net turnover during the day was Rs. 376353216.

Source : Equity Bulls

Keywords